CPI-1189
(Synonyms: N-叔丁基-4-乙酰氨基苯甲酰胺) 目录号 : GC14500
A benzamide
Cas No.:183619-38-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
CPI-1189 is a proapoptotic cytokine tumor necrosis factor (TNF) alpha inhibitor.
AIDS dementia complex is characterized by increased gliosis, apoptosis, and oxidative stress in the CNS, as well as a compromised blood-brain barrier. TNF-alpha has been reported to be elevated in AIDS dementia complex brains and may contribute to AIDS dementia complex.
In vitro: CPI-1189 could potently inhibit p38-MAPK phosphorylation displaying protective action against tumor necrosis factor-alpha (TNFalpha)-induced neurodegeneration. Moreover, in primary astrocytes treated with interleukin 1beta, CPI-1189 inhibited p38-MAPK phosphorylation at low concentrations [1].
In vivo: To model elevated TNF-alpha in AIDS dementia complex, TNF-alpha was infused into rats. Results showed that the co-administration of CPI-1189 prevented TNF-alpha induced apoptosis. Both TNF-alpha and CPI-1189 treatment could suppress glial fibrillary acidic protein staining. TNF-alpha alone did not affect the integrity of the blood-brain barrier significantly, but CPI-1189 treatment increased blood-brain barrier integrity [2].
Clinical trial: Previous clinical study showed that CPI-1189 was well tolerated, with 91% of CPI-1189-treated subjects and 76% of placebo-treated subjects completing the trial. Skin rash was equally found in placebo and drug-treated arms. One subject developed a cataract on CPI-1189. CD4 lymphocyte counts and plasma HIV viral load remained stable in all groups throughout the trial [3].
References:
[1] Hensley K,Robinson KA,Pye QN,Floyd RA,Cheng I,Garland WA,Irwin I. CPI-1189 inhibits interleukin 1beta-induced p38-mitogen-activated protein kinase phosphorylation: an explanation for its neuroprotective properties Neurosci Lett.2000 Mar 10;281(2-3):179-82.
[2] Bjugstad KB,Flitter WD,Garland WA,Philpot RM,Kirstein CL,Arendash GW. CPI-1189 prevents apoptosis and reduces glial fibrillary acidic protein immunostaining in a TNF-alpha infusion model for AIDS dementia complex. J Neurovirol.2000 Dec;6(6):478-91.
[3] Clifford DB,McArthur JC,Schifitto G,Kieburtz K,McDermott MP,Letendre S,Cohen BA,Marder K,Ellis RJ,Marra CM;Neurologic AIDS Research Consortium. A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology.2002 Nov 26;59(10):1568-73.
| Cas No. | 183619-38-7 | SDF | |
| 别名 | N-叔丁基-4-乙酰氨基苯甲酰胺 | ||
| 化学名 | (Z)-N-(4-(tert-butylcarbamoyl)phenyl)acetimidic acid | ||
| Canonical SMILES | C/C(O)=N/C1=CC=C(C=C1)C(NC(C)(C)C)=O | ||
| 分子式 | C13H18N2O2 | 分子量 | 234.29 |
| 溶解度 | ≥ 23.4mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.2682 mL | 21.3411 mL | 42.6821 mL |
| 5 mM | 0.8536 mL | 4.2682 mL | 8.5364 mL |
| 10 mM | 0.4268 mL | 2.1341 mL | 4.2682 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。